OncoMatch

OncoMatch/Clinical Trials/NCT04864054

T-Cell Therapy (ECT204) in Adults With Advanced HCC

Is NCT04864054 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ECT204 T cells for hepatocellular carcinoma.

Phase 1/2RecruitingEureka Therapeutics Inc.NCT04864054Data as of May 2026

Treatment: ECT204 T cellsThis is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Biomarker criteria

Required: GPC3 positive (IHC ≥10-20% tumor cells, ≥2+ (dose-escalation cohort); IHC ≥50% tumor cells, 2+/3+ (RP2D cohort))

GPC3-positive tumor expression confirmed by immunohistochemistry (IHC). For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC. Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+/3+ IHC.

Prior therapy

Min 2 prior lines

Must have received: anti-HCC systemic agent

Must have failed, or not tolerated, at least two (2) different anti-HCC systemic agents.

Cannot have received: liver tumor-directed therapy

Exception: must be >14 days from date of consent

Currently receiving or ending (< 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery.

Lab requirements

Liver function

Child-Pugh score of A6 or better.

Child-Pugh score of A6 or better. Adequate organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California
  • Kansas University Medical Center, Principal Investigator: · Westwood, Kansas
  • Roswell Park Comprehensive Cancer Center · Buffalo, New York
  • Oregon Health and Sciences University · Portland, Oregon
  • University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center · Dallas, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify